[ad_1]
Bonatra increasing persistent illness administration platform with MyAva acquisition
Bonatra, which is as soon as targeted on treating persistent well being circumstances in males, is increasing its platform to cope with girls’s well being and wellness by way of its newest acquisition of MyAva.
Based in 2019, the femtech startup gives curated programmes and personalised plans to assist girls handle their persistent circumstances, together with PCOS and thyroid issues.
“Buying MyAva permits us to increase our attain and deepen our experience in girls’s well being, particularly for circumstances like PCOS,” stated Bonatra CEO and co-founder Rahul Kishore Singh. Bonatra provides personalised therapy plans based mostly on IoMT-collected knowledge to assist males deal with and handle their persistent circumstances, corresponding to hypertension and diabetes.
MyAva CEO and founder stated they’re elated to affix Bonatra and “additional the imaginative and prescient of creating persistent care administration accessible to all girls” whereas strengthening their joint commitments to “making femtech extra inclusive and built-in.”
Startoon will get US FDA clearance for wearable restoration monitoring gadget
Indian medical gadget startup Startoon Labs has acquired the US Meals and Drug Administration’s 510(okay) clearance for its flagship wearable well being product.
Known as Pheezee, the gadget measures the floor electromyogram of bulk muscle tissue and the vary of movement of major joints to find out joint well being. It’s meant to be used in monitoring sufferers’ restoration from physiotherapy, neurological, and musculoskeletal accidents.
Indian researchers use ML to detect CNS tumours
Researchers on the Indian Institute of Expertise Madras have developed an ML-based computational software to raised detect cancer-causing tumours within the mind and spinal twine.
Out there publicly on-line, the GBMDriver (GlioBlastoma Mutiforme Drivers) identifies driver mutations and passenger mutations in glioblastoma, that are key to creating therapeutic choices for sufferers.
Ubie expands uncommon ailments partnership with Takeda
Japanese well being tech startup Ubie has expanded its digital transformation partnership with Takeda Pharmaceutical Co.
The expanded collaboration, in line with a press assertion, seeks to advertise the early detection of uncommon ailments and gastrointestinal ailments. The 2 firms began their partnership in 2021 with the promotion of Ubie’s symptom checker and affected person consumption kind.
Ubie additionally intends to introduce further capabilities on high of its present choices and to collaborate with Takeda on IT methods and knowledge.
[ad_2]
Source link